Online Formulary
Using the Formulary
Therapeutic Sections
1. Gastro-intestinal system
2. Cardiovascular system
3. Respiratory
4. Nervous system
5. Infection
6. Endocrine system
7. Genito-urinary system
8. Immune System
8. Malignant disease
9. Blood and blood-forming organs
9. Nutrition and metabolic disorders
10. Musculoskeletal system
11. Eye
12. Ear
12. Nose
12. Oropharynx
13. Skin
14. Vaccines
15. Anaesthesia
16. Emergency Treatment of Poisoning
Palliative Care
Wound management products
Stoma products
Continence products
Borderline substances
General recommendations and information
Shared Care
Using the Formulary
Therapeutic Sections
1. Gastro-intestinal system
2. Cardiovascular system
3. Respiratory
4. Nervous system
5. Infection
6. Endocrine system
7. Genito-urinary system
8. Immune System
8. Malignant disease
8.2 Antibody responsive malignancy
8.3 Carcinoid syndrome
8.4 Cytotoxic responsive malignancy
8.5 Hormone responsive malignancy
8.6 Immunotherapy responsive malignancy
8.7 Photodynamic therapy responsive malignancy
8.8 Targeted therapy responsive malignancy
Local recommendations (Malignant disease)
9. Blood and blood-forming organs
9. Nutrition and metabolic disorders
10. Musculoskeletal system
11. Eye
12. Ear
12. Nose
12. Oropharynx
13. Skin
14. Vaccines
15. Anaesthesia
16. Emergency Treatment of Poisoning
Palliative Care
Wound management products
Stoma products
Continence products
Borderline substances
General recommendations and information
Shared Care
Search
Feedback
Drug Status Key
On Formulary
Specialist Initiation
Shared Care
Hospital Only
Not Recommended
Preferences
First Line
Second Line
Third Line
No Preference
Local recommendations (Malignant disease)
Recommendation
Approval date
Review date
Degarelix prescribing guidelines EKPG
April 2015
April 2021
Immunosuppressant Prescribing Update
June 2016
June 2019
Oral Methotrexate Kent and Medway Position Statement
December 2020
December 2022